MarketPeel
Insider Trading Intelligence
DT

Dan Benjamin Teleman

NSRX
CHIEF EXECUTIVE OFFICER · NASUS PHARMA LTD · CIK 0002122500
FILING MIX · LIFETIME100%/0%
BUYS
3
SELLS
0
TOTAL VALUE
$61.8K
COMPANIES
1
ACTIVE SINCE
Mar 2026
HOLDINGS NOW
163,541
AVG SELL PX
TRADE KIND
SHOWING 3 / 3
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 7 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Dan Benjamin Teleman, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+50.00%-16.19%+0.71%-16.90%-16.90%
14d2+50.00%-8.96%+4.98%-13.95%-13.95%
30d2+100.00%+21.62%+10.51%+11.12%+11.12%
60d2+50.00%+11.53%+5.00%-26.07%-26.07%
90d2(1 pending)+100.00%+48.65%+12.09%+36.55%+36.55%
180d2(2 pending)
1y2(2 pending)
2y2(2 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
NSRX · 163,541 shares · as of Jun 17, 2026
040,88581,771122,656163,541SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2026
2026
FLOW · 3 buys / 0 sellsCOVERAGE · 2 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
NSRX
NASUS PHARMA LTD
PURCHASE
Chief Executive Officer
6,550$3.10$20.3K163,541Jun 17, 2026Jun 22, 2026View →
NSRX
NASUS PHARMA LTD
PURCHASE
Chief Executive Officer
2,900$3.76$10.9K156,991Apr 22, 2026Apr 22, 2026View →
NSRX
NASUS PHARMA LTD
PURCHASE
Chief Executive Officer
15,000$2.04$30.6K21,246Mar 31, 2026Apr 1, 2026View →
Other insiders · NSRX
Loading peer insiders…
About this filer
CIK 0002122500
ROLE
Chief Executive Officer
PRIMARY
NSRX
COMPANIES
1
ACTIVE SINCE
Mar 2026
MARKETPEEL · /INSIDER/0002122500DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback